| Biotechnology Industry | Healthcare Sector | Stephen Van Deventer CEO | OTCQB Exchange | CA74143C1068 ISIN |
| CA Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
PreveCeutical Medical Inc. is a health sciences enterprise focused on the creation of preventive and curative treatments that incorporate organic and nature identical substances. The company is pioneering in its approach to addressing significant health issues by working on a pipeline of innovative product solutions with applications ranging from pain management to combating severe diseases such as cancer and diabetes. With its headquarters located in Vancouver, Canada, PreveCeutical Medical Inc. is steadfast in its mission to deliver groundbreaking health solutions that can offer relief and improve the quality of life for patients around the globe.
This cutting-edge delivery system leverages the therapeutic potentials of cannabinoids by facilitating a direct nose-to-brain transportation method. The solvent gel technology is designed to offer a non-invasive, efficient solution for treating conditions such as pain, inflammation, seizures, and neurological disorders without the side effects commonly associated with conventional drug delivery systems.
In response to the global opioid crisis, PreveCeutical Medical Inc. is developing a non-addictive analgesic for pain management. This initiative aims to provide patients suffering from chronic and acute pain a safer, effective alternative to opioid medications, thus significantly reducing the risk of addiction and other related complications.
The BSV Peptide Program targets the biochemical pathways involved in cancer progression, offering a novel approach to cancer therapy. By focusing on specific peptides that can alter the behavior of cancer cells, this program seeks to reduce tumor growth, prevent metastasis, and potentially enhance the effectiveness of existing cancer treatments through synergy.
Addressing two of the most prevalent chronic conditions worldwide, the dual gene therapy program is poised to revolutionize the treatment landscape for type 2 diabetes and obesity. By targeting the genetic underpinnings of these diseases, PreveCeutical aims to deliver a therapeutic solution that not only manages symptoms but also addresses the root causes, offering a path towards lasting health improvements.
Expanding its portfolio, PreveCeutical Medical Inc. is also venturing into the development of medicinal cannabis-based products. Recognizing the versatile therapeutic potential of cannabis, the company is exploring various formulations and delivery mechanisms to treat a wide array of conditions, emphasizing safety, efficacy, and patient convenience.